Alberto sales
This article was originally published in The Rose Sheet
Executive Summary
Alberto-Culver will consider acquiring Keri Lotion from Bristol-Myers Squibb and has made its interest known, President and CEO Howard Bernick states during a Jan. 27 fiscal first quarter sales and earnings (ended Dec. 31) analyst call. Bernick has been eyeing Keri as a fit with Alberto's portfolio for a number of years. However, it is anticipated BMS will sell the U.S. and Canadian Consumer Medicines business as one unit, in which case Bernick says he hopes the potential buyer may be looking to shed Keri. First quarter sales, up 10.8% to $848 mil., were driven by consumer products (up 9.4% to $303.7 mil.) and beauty supply distribution (up 12.1% to $550.8 mil.), the firm reports. Net earnings were $51.9 mil., up 21.2%, excluding a $2.5 mil. non-cash charge related to the company's stock conversion. Including charges in both the year ago and current period, net earnings were $49.4 mil., compared to $1.7 mil. a year ago...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.